Figure 3.

Expression of NDUFA4L2 in hypoxic HPASMCs and HPAECs. A, Real‐time PCR analysed NDUFA4L2 mRNA expression in HPAECs at different time‐points of hypoxia; (B) Western blotting analysed NDUFA4L2 protein expression in HPAECs at different time‐points of hypoxia; (C) Western blotting analysed NDUFA4L2 protein expression in HPASMCs at different time‐points of hypoxia; (D) Western blotting analysed HIF1α protein expression in HPASMCs at different time‐points of hypoxia; (E)The efficiency and specificity of siRNA directed against HIF1α (si‐HIF1α); (F) After interference with HIF1α, Western blotting was used to detect the expression of NDUFA4L2 in hypoxic HPASMCs. NC, negative control; Nor, normoxia; Hyp, hypoxia. ^* P < .05, ^** P < .01, ^*** P < .001. n = 6. All of the values are denoted as mean ± SEM